Literature DB >> 22051332

Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction.

Paul M McKie1, John A Schirger, Lisa C Costello-Boerrigter, Sherry L Benike, Lynn K Harstad, Kent R Bailey, David O Hodge, Margaret M Redfield, Robert D Simari, John C Burnett, Horng H Chen.   

Abstract

OBJECTIVES: We hypothesized an impaired renal endocrine and natriuretic response to volume expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dysfunction (PDD). We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD.
BACKGROUND: Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriuretic response to acute VE.
METHODS: PSD was defined as left ventricular ejection fraction <40% without HF symptoms. PDD was defined as ejection fraction >50%, moderate to severe diastolic dysfunction by Doppler criteria, and no HF symptoms. A double-blinded, placebo-controlled, crossover study was employed to determine the renal response to VE (0.25 ml/kg/min of normal saline for 60 min) in the presence and absence of exogenous BNP. Twenty healthy control subjects, 20 PSD subjects, and 18 PDD subjects participated.
RESULTS: In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased after VE. In contrast, among PSD and PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated natriuresis. Pre-treatment with subcutaneous BNP resulted in similar increases in both urinary cGMP and natriuresis among healthy normal, PSD, and PDD subjects.
CONCLUSIONS: In PSD and PDD, there is impaired renal cGMP activation, which contributes to impaired natriuresis in response to VE. Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume overload and the progression of HF among PSD and PDD subjects. Importantly, the impaired renal excretory response to VE is rescued by exogenous BNP in PSD and PDD. Copyright Â
© 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22051332      PMCID: PMC3835631          DOI: 10.1016/j.jacc.2011.07.042

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

1.  Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading.

Authors:  H Tomiyama; G Watanabe; M Abe; R Okazaki; H Yoshida; N Doba
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

2.  Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study.

Authors:  S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

3.  Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure.

Authors:  H H Chen; J A Schirger; W L Chau; M Jougasaki; O Lisy; M M Redfield; P T Barclay; J C Burnett
Journal:  Circulation       Date:  1999-12-14       Impact factor: 29.690

4.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

5.  Long-term trends in the incidence of and survival with heart failure.

Authors:  Daniel Levy; Satish Kenchaiah; Martin G Larson; Emelia J Benjamin; Michelle J Kupka; Kalon K L Ho; Joanne M Murabito; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

6.  Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria.

Authors:  Horng H Chen; John G Lainchbury; Michele Senni; Kent R Bailey; Margaret M Redfield
Journal:  J Card Fail       Date:  2002-10       Impact factor: 5.712

7.  Plasma brain natriuretic peptide concentration: impact of age and gender.

Authors:  Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

8.  Natural history of asymptomatic left ventricular systolic dysfunction in the community.

Authors:  Thomas J Wang; Jane C Evans; Emelia J Benjamin; Daniel Levy; Elizabeth C LeRoy; Ramachandran S Vasan
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

9.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Atrial natriuretic peptide elevation in congestive heart failure in the human.

Authors:  J C Burnett; P C Kao; D C Hu; D W Heser; D Heublein; J P Granger; T J Opgenorth; G S Reeder
Journal:  Science       Date:  1986-03-07       Impact factor: 47.728

View more
  23 in total

Review 1.  New insights into combinational drug therapy to manage congestion in heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 2.  Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Authors:  Paul M McKie; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 3.  Management of the cardiorenal syndrome in decompensated heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Cardiorenal Med       Date:  2014-12       Impact factor: 2.041

Review 4.  SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys.

Authors:  Frederik H Verbrugge; Pieter Martens; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2017-08

5.  Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study.

Authors:  Javed Butler; Lampros Papadimitriou; Vasiliki Georgiopoulou; Hal Skopicki; Sandra Dunbar; Andreas Kalogeropoulos
Journal:  Circ Heart Fail       Date:  2015-05       Impact factor: 8.790

Review 6.  Heart failure with preserved ejection fraction in the elderly: scope of the problem.

Authors:  Bharathi Upadhya; George E Taffet; Che Ping Cheng; Dalane W Kitzman
Journal:  J Mol Cell Cardiol       Date:  2015-03-06       Impact factor: 5.000

7.  Update on heart failure with preserved ejection fraction.

Authors:  Scott L Hummel; Dalane W Kitzman
Journal:  Curr Cardiovasc Risk Rep       Date:  2013-12

8.  Impact of Ultrafiltration on Serum Sodium Homeostasis and its Clinical Implication in Patients With Acute Heart Failure, Congestion, and Worsening Renal Function.

Authors:  Takeshi Kitai; Justin L Grodin; Yong-Hyun Kim; W H Wilson Tang
Journal:  Circ Heart Fail       Date:  2017-02       Impact factor: 8.790

Review 9.  Pre-clinical diastolic dysfunction.

Authors:  Siu-Hin Wan; Mark W Vogel; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

Review 10.  Utility of Urine Biomarkers and Electrolytes for the Management of Heart Failure.

Authors:  Frederik Hendrik Verbrugge
Journal:  Curr Heart Fail Rep       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.